நம்பிக்கையற்ற மேம்பாடுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நம்பிக்கையற்ற மேம்பாடுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நம்பிக்கையற்ற மேம்பாடுகள் Today - Breaking & Trending Today

Investegate |Coherus BioSciences, Inc. Announcements | Coherus BioSciences, Inc.: Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement.
“We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and promising PD-1 combination candidates,” said Dr. Ning LI, CEO of Junshi Biosciences. “We wanted to invest in Coherus so we could share our future growth together and mutual success with these programs.” ....

United States , San Francisco , Denny Lanfear , Hart Scott Rodino , Mcdavid Stilwell , Junshi Bioscience , Junshi Biosciences , Eli Lilly , Institute Of Microbiology Chinese Academy Science , Coherus Biosciences Inc , Genentech Inc , Shanghai Junshi Biosciences Co Ltd , Committee On Foreign Investment , Exchange Commission , Abbvie Inc , Coherus Biosciences , Strategic Investment , Immuno Oncology Partner Junshi , Antitrust Improvements , Microbiology Chinese Academy , Private Securities Litigation Reform Act , Antitrust Improvements Act , Foreign Investment , Coheru Annual Report , Quarterly Report , Financial Strategy ,

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi .
Coherus BioSciences, Inc.February 1, 2021 GMT
- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody
- First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation
- Options to PD-1 combination agents, TIGIT and IL-2, add long-term growth potential
- Conference call at 8:00 am Eastern Time today
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced a collaboration with Shanghai Junshi Biosciences, Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the Uni ....

United States , San Francisco , Denny Lanfear , Jonathan Lanfear , Sunitinib Monotherapy , Hart Scott Rodino , Junshi Bioscience , Eli Lilly , Mcdavid Stilwell , Junshi Biosciences , Coherus Biosciences Inc , Ropes Gray , Committee On Foreign Investment , China National Medical Products Administration , Abbvie Inc , Co Ltd Junshi Biosciences , Regeneron Pharmaceuticals Inc , Institute Of Microbiology Chinese Academy Science , Drug Administration , Lanfear Advisors , Genentech Inc , China National Healthcare Security Administration , Exchange Commission , National Reimbursement Drug List , Eastern Time , Shanghai Junshi Biosciences ,

ZAGG Inc to be Acquired by Buyer Group Led by Evercel, Inc.

Share:
SALT LAKE CITY, Dec. 11, 2020 (GLOBE NEWSWIRE) ZAGG Inc (NASDAQ:ZAGG) ( we, us, our, ZAGG, or the Company ), a leading global mobile lifestyle company, and a buyer group (the Buyer Group ) led by Evercel, Inc. ( Evercel ), today announced that they have entered into a definitive agreement pursuant to which the Buyer Group will acquire all of the issued and outstanding common stock of the Company for up to $4.45 per share in cash. Stockholders will receive $4.20 per share in cash upon closing and will be entitled to receive an additional contingent amount of up to $0.25 per share, to be paid if the Company s Paycheck Protection Program Loan (the PPP Loan ) is forgiven and any audit related thereto is satisfactorily completed. The transaction is expected to close in the first quarter of 2021. The terms of the agreement, which has been unanimously approved by the Company s Board of Directors, will be submitted for approval of the Company s stockholders. ....

United States , Daniel Allen , Chris Ahern , Brendon Frey , Jeff Dubois , Evercel Inc , Oppenheimer Co , Us Small Business Administration , Lewis Bockius , Company Paycheck Protection Program Loan , Company Board Of Directors , Latham Watkins , Exchange Commission , Buyer Group , Securities Exchange , Grant Thornton , Best Buy , Lincoln International , Paycheck Protection Program Loan , Chief Executive Officer , Antitrust Improvements , Business Administration , Securities Litigation Reform Act , Annual Report , Financial Condition , Securities Act ,